Patent application number | Description | Published |
20110043361 | HAZARD ALARM WITH A VARIABLE HOLDING REGION FOR A SUPPLY ELEMENT - A danger sensor ( | 02-24-2011 |
20110255091 | ADAPTING A SCANNING POINT OF A SAMPLE AND HOLD CIRCUIT OF AN OPTICAL SMOKE DETECTOR - A smoke detector contains a radiation source for transmitting an illuminating radiation having a time sequence of radiation pulses, a radiation detector for receiving measurement radiation impinging on the radiation detector after at least partial scattering of the illuminating radiation, an amplifier circuit for amplifying an output signal of the radiation detector, an analog to digital converter having a sample and hold circuit for converting an analog output signal of the amplifier circuit into a digital measurement value, and a control device coupled to the radiation source and the sample and hold circuit. The control device is equipped for controlling the radiation source and the sample and hold circuit such that the time of a sampling point in time of the sample and hold circuit relative to a radiation pulse depends on the duration of the radiation pulse. A method for calibrating the described smoke detector is also revealed. | 10-20-2011 |
20120092176 | CALIBRATION OF AN ELECTRO-OPTICAL SIGNAL PATH OF A SENSOR DEVICE BY ONLINE SIGNAL LEVEL MONITORING - A sensor device detects an object, in particular for optically detecting smoke particles. The sensor device contains a transmitting device for emitting transmit radiation, a receiving device for receiving receive radiation having scattering radiation that is generated by an at least partial scattering of the transmit radiation by the object, and for outputting a measurement signal indicative of the receive radiation, a signal modification device for modifying the measurement signal and for outputting a modified measurement signal, a level of the modified measurement signal increasing after the transmitting device has been switched on, and a calibration device for monitoring the modified measurement signal. The calibration device is embodied such that a reaching of a predefined signal level for the modified measurement signal can be detected and that a time interval between the switching on of the transmitting device and the reaching of the predefined signal level can be determined. | 04-19-2012 |
20130120150 | DANGER DETECTOR FOR OPERATION IN NUCLEAR FIELD, HAVING HEATING SYSTEM FOR HEATING TYPICALLY NON-RADIATION HARDENED SEMICONDUCTOR COMPONENTS TO INCREASE FUNCTIONAL SERVICE LIFE - A smoke detector or, more generally, a danger detector, operates in an area with increased radioactive radiation disposition danger detector has at least one detector unit for detecting at least one danger characteristic, a semiconductor component and other electrical components, at least for outputting an alarm signal. The danger detector also has a temperature control circuit. The temperature control circuit is configured to control the temperature of the at least one semiconductor component. The danger detector may be embodied as a linear smoke detector. | 05-16-2013 |
20140097958 | INTEGRATED CIRCUIT TO OPERATE IN AN AREA OF IONIZING RADIATION, AND HAVING AN OUTPUT FOR A RADIATION DOSE-DEPENDENT WAY DAMAGE INFORMATION, AND ALARM INDICATORS AND CORRESPONDING METHOD - An integrated circuit, in particular a microcontroller, for operation in an area with ionizing radiation, has at least one part of a temperature control circuit. The temperature control circuit performs a regulated increase in the circuit temperature to a predefined, essentially constant operating temperature, by increasing the electrical power consumption of the circuit by an adjustable additional electrical power. The circuit has an output facility for information about damage to the integrated circuit caused by the ionizing radiation impacting thereon, it being possible to determine the information about damage from a radiation-dose-dependent decrease in the adjustable additional electrical power. | 04-10-2014 |
Patent application number | Description | Published |
20100216180 | METHODS OF USING HALOGENATED PEPTIDES AS INTERNAL STANDARDS FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY - Methods of using halogenated peptides as internal standards for liquid chromatography-mass spectrometry, and novel halogenated peptides useful for the same, are disclosed. In particular, methods of using halogenated peptides as internal standards in proteomic analyses, as well as methods of using halogenated peptides to conduct quality control assessments of and/or to calibrate liquid chromatography-mass spectrometry systems are disclosed. | 08-26-2010 |
20110065605 | METHOD FOR BIOMARKER AND DRUG-TARGET DISCOVERY FOR PROSTATE CANCER DIAGNOSIS AND TREATMENT AS WELL AS BIOMARKER ASSAYS DETERMINED THEREWITH - The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein/peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behaviour between healthy and cancerous sample proteomes; (c) validation of the candidate protein/peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein/peptide biomarkers those which show a mass-spectrometrically measurable and/or antibody-based assay detectable differential behaviour between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein/peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself. | 03-17-2011 |
20130193317 | METHODS OF USING HALOGENATED PEPTIDES AS INTERNAL STANDARDS FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY - Methods of using halogenated peptides as internal standards for liquid chromatography-mass spectrometry, and novel halogenated peptides useful for the same, are disclosed. In particular, methods of using halogenated peptides as internal standards in proteomic analyses, as well as methods of using halogenated peptides to conduct quality control assessments of and/or to calibrate liquid chromatography-mass spectrometry systems are disclosed. | 08-01-2013 |
20130206979 | Data Independent Acquisition of Product Ion Spectra and Reference Spectra Library Matching - Systems and methods are used to store an electronic record of all product ion spectra of all detectable compounds of a sample. A plurality of product ion scans are performed on a tandem mass spectrometer one or more times in a single sample analysis across a mass range using a plurality of mass selection windows. All sample product ion spectra of all detectable compounds for each mass selection window are produced. All sample product ion spectra for each mass selection window are received from the tandem mass spectrometer using a processor. All sample product ion spectra for each mass selection window are stored as an electronic record of all detectable compounds of the sample using the processor. The electronic record is used to characterize compounds known at the time the electronic record is stored or to characterize compounds that became known after the electronic record was stored. | 08-15-2013 |
20140322732 | METHOD FOR BIOMARKER AND DRUG-TARGET DISCOVERY FOR PROSTATE CANCER DIAGNOSIS AND TREATMENT AS WELL AS BIOMARKER ASSAYS DETERMINED THEREWITH - The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein/peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behaviour between healthy and cancerous sample proteomes; (c) validation of the candidate protein/peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein/peptide biomarkers those which show a mass-spectrometrically measurable and/or antibody-based assay detectable differential behaviour between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein/peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself. | 10-30-2014 |
20150144778 | Data Independent Acquisition of Product Ion Spectra and Reference Spectra Library Matching - Systems and methods are used to store an electronic record of all product ion spectra of all detectable compounds of a sample. A plurality of product ion scans are performed on a tandem mass spectrometer one or more times in a single sample analysis across a mass range using a plurality of mass selection windows. All sample product ion spectra of all detectable compounds for each mass selection window are produced. All sample product ion spectra for each mass selection window are received from the tandem mass spectrometer using a processor. All sample product ion spectra for each mass selection window are stored as an electronic record of all detectable compounds of the sample using the processor. The electronic record is used to characterize compounds known at the time the electronic record is stored or to characterize compounds that became known after the electronic record was stored. | 05-28-2015 |
Patent application number | Description | Published |
20090111195 | CHEMICAL REAGENTS AND METHODS FOR DETECTION AND QUANTIFICATION OF PROTEINS IN COMPLEX MIXTURES - The invention provides a reagent comprising an affinity tag, a detectable moiety, a linker, an isotope tag and a reactive group. The invention also provides methods of using a reagent of the invention. The methods can be used to label a polypeptide in a sample by contacting a sample with a reagent of the invention under conditions allowing the reactive group to bind to one or more polypeptides in the sample. The invention additionally provides methods of isolating, identifying and quantifying a polypeptide in a sample. The invention further provides methods of diagnosing a disease using a reagent of the invention. | 04-30-2009 |
20100196883 | ANDROGEN-REGULATED GENES AND USES FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE NEOPLASTIC CONDITIONS - The invention provides a method for diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual. The method involves (a) determining a level of RDC1 in a sample from the individual, and (b) comparing the level of RDC1 in the sample to a reference level of RDC1, wherein a level of RDC1 in the sample 2-fold or more higher than the reference level indicates the presence of, or susceptibility to, a prostate neoplastic condition in the individual. | 08-05-2010 |
20100267577 | Methods for high throughput and quantitative proteome analysis - The invention provides methods for identifying and quantifying polypeptides in a sample. The methods include the steps of labeling peptides in a polypeptide sample with an isotope tag; adding a plurality of peptide standards to the polypeptide sample, wherein the peptide standards are labeled with an isotopically distinct version of the isotope tag; resolving the labeled sample and standard peptides into a plurality of fractions; analyzing the resolved fractions using mass spectrometry; identifying an isotope-tagged sample peptide in an analyzed fraction; and determining the amount of the identified isotope-tagged sample peptide in the analyzed fraction by comparison to the amount of isotope tagged standard peptide in the same fraction. | 10-21-2010 |